Comparing Enanta Pharmaceuticals (ENTA) & The Competition

Enanta Pharmaceuticals (NASDAQ:ENTA) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Enanta Pharmaceuticals to similar companies based on the strength of its institutional ownership, profitability, risk, valuation, dividends, earnings and analyst recommendations.

Profitability

This table compares Enanta Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%
Enanta Pharmaceuticals Competitors	-2,380.61%	-219.90%	-15.56%

Analyst Recommendations

This is a breakdown of current ratings for Enanta Pharmaceuticals and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1	0	3	0	2.50
Enanta Pharmaceuticals Competitors	7776	13772	25741	1037	2.41

Enanta Pharmaceuticals currently has a consensus target price of $19.00, suggesting a potential upside of 63.79%. As a group, “Pharmaceuticals” companies have a potential upside of 24.80%. Given Enanta Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts plainly believe Enanta Pharmaceuticals is more favorable than its competitors.

Insider & Institutional Ownership

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 11.5% of Enanta Pharmaceuticals shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Enanta Pharmaceuticals has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals’ competitors have a beta of -3.81, meaning that their average stock price is 481% less volatile than the S&P 500.

Earnings & Valuation

This table compares Enanta Pharmaceuticals and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32 million	-$81.89 million	-4.81
Enanta Pharmaceuticals Competitors	$3.56 billion	$3.19 billion	552.49

Enanta Pharmaceuticals’ competitors have higher revenue and earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Enanta Pharmaceuticals beats its competitors on 7 of the 13 factors compared.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc. is a biotechnology company based in Watertown, Massachusetts, that discovers and develops small-molecule medicines. Its research has focused on infectious diseases and inflammatory conditions, including respiratory syncytial virus (RSV), hepatitis B and immunology. Enanta’s work with AbbVie contributed to the discovery of glecaprevir, an antiviral used with pibrentasvir in the hepatitis C treatment Mavyret. The collaboration reflects the company’s history of applying its drug-discovery expertise to antiviral therapies.